Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells

被引:45
作者
Clodi, K
Asgary, Z
Zhao, SR
Kliche, KO
Cabanillas, F
Andreeff, M
Youns, A
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Lymphoma, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Mol Hematol, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Therapy, Houston, TX 77030 USA
关键词
CD40; lymphoma; ligand; leukaemia; GVHD;
D O I
10.1046/j.1365-2141.1998.01031.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
CD40 ligand (CD40L) is involved in the T-cell-dependent regulation of B-cell growth and survival and can rescue normal germinal centre B cells and several types of malignant B cells from apoptosis in vitro, We have previously reported that serum of patients with chronic lymphocytic leukaemia contained elevated levels of biologically active soluble CD40L (sCD40L). Whether an augmented CD40L pathway exists in patients with other types of B-cell lymphoid malignancies and the source of native sCD40L in these patients is currently unknown. Using a sensitive ELISA assay, soluble CD40L (sCD40L) was detected in the sera of both healthy individuals and patients with haematological malignancies: however, its level was significantly elevated only in patients with B-cell lymphomas (P<0.0001). Several types of malignant B cells coexpressed CD40 and CD40L proteins, and CD40L mRNA was detected in purified resting malignant B cells. The dual expression of CD40 and CD40L in B cells and the presence of native sCD40L in human serum suggest that a direct T-B-cell contact may not be required for CD40L delivery to B cells. This data raises the possibility that an autocrine cytokine loop involving CD40L may contribute to the growth regulation of benign and malignant B cells in vivo.
引用
收藏
页码:270 / 275
页数:6
相关论文
共 23 条
[1]   Hierarchical control of lymphocyte survival [J].
Boise, LH ;
Thompson, CB .
SCIENCE, 1996, 274 (5284) :67-68
[2]   In vitro activation of low-grade non-Hodgkin's lymphoma by murine fibroblasts, IL-4, anti-CD40 antibodies and the soluble CD40 ligand [J].
Buske, C ;
Twiling, A ;
Gogowski, G ;
Schreiber, K ;
FeuringBuske, M ;
Wulf, GG ;
Hiddemann, W ;
Wormann, B .
LEUKEMIA, 1997, 11 (11) :1862-1867
[3]  
CLODI K, 1998, IN PRESS BRIT J HAEM
[4]   Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity [J].
Drappa, J ;
Vaishnaw, AK ;
Sullivan, KE ;
Chu, JL ;
Elkon, KB .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (22) :1643-1649
[5]   ANTIBODY TO THE LIGAND OF CD40, GP39, BLOCKS THE OCCURRENCE OF THE ACUTE AND CHRONIC FORMS OF GRAFT-VS-HOST DISEASE [J].
DURIE, FH ;
ARUFFO, A ;
LEDBETTER, J ;
CRASSI, KM ;
GREEN, WR ;
FAST, LD ;
NOELLE, RJ .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (03) :1333-1338
[6]   Expression of several members of the TNF-ligand and receptor family on tonsillar lymphoid B cells [J].
Durkop, H ;
Anagnostopoulos, I ;
BulfonePaus, S ;
Stein, H .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 98 (04) :863-868
[7]   Unbalanced expression of bcl-2 family proteins in follicular lymphoma: Contribution of CD40 signaling in promoting survival [J].
Ghia, P ;
Boussiotis, VA ;
Schultze, JL ;
Cardoso, AA ;
Dorfman, DM ;
Gribben, JG ;
Freedman, AS ;
Nadler, LM .
BLOOD, 1998, 91 (01) :244-251
[8]  
GRAMMER AC, 1995, J IMMUNOL, V154, P4996
[9]   SUPPRESSION OF APOPTOSIS IN NORMAL AND NEOPLASTIC HUMAN B-LYMPHOCYTES BY CD40 LIGAND IS INDEPENDENT OF BC1-2 INDUCTION [J].
HOLDER, MJ ;
WANG, H ;
MILNER, AE ;
CASAMAYOR, M ;
ARMITAGE, R ;
SPRIGGS, MK ;
FANSLOW, WC ;
MACLENNAN, ICM ;
GREGORY, CD ;
GORDON, J .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1993, 23 (09) :2368-2371
[10]   ISOLATED FOLLICULAR LYMPHOMA-CELLS ARE RESISTANT TO APOPTOSIS AND CAN BE GROWN IN-VITRO IN THE CD40 STROMAL CELL SYSTEM [J].
JOHNSON, PWM ;
WATT, SM ;
BETTS, DR ;
DAVIES, D ;
JORDAN, S ;
NORTON, AJ ;
LISTER, TA .
BLOOD, 1993, 82 (06) :1848-1857